Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Identifieur interne : 001B84 ( Main/Merge ); précédent : 001B83; suivant : 001B85Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Auteurs : Hann-Chorng Kuo [Taïwan] ; Hsin-Tzu Liu [Taïwan] ; Yao-Chi Chuang [Taïwan] ; Lori A. Birder [États-Unis] ; Michael B. Chancellor [États-Unis]Source :
- European urology [ 1873-7560 ] ; 2014.
Descripteurs français
- KwdFr :
- Administration par voie vésicale, Adulte, Adulte d'âge moyen, Femelle, Glycoprotéines membranaires (analyse), Humains, Inhibiteurs de la libération d'acétylcholine (administration et posologie), Inhibiteurs de la libération d'acétylcholine (effets indésirables), Liposomes, Miction (), Mâle, Méthode en double aveugle, Projets pilotes, Protéine SNAP-25 (analyse), Protéines de tissu nerveux (analyse), Sujet âgé, Sujet âgé de 80 ans ou plus, Toxines botuliniques de type A (administration et posologie), Toxines botuliniques de type A (effets indésirables), Urodynamique (), Urothélium (), Vessie hyperactive (métabolisme), Vessie hyperactive (physiopathologie), Vessie hyperactive (traitement médicamenteux), Vessie urinaire ().
- MESH :
- administration et posologie : Inhibiteurs de la libération d'acétylcholine, Toxines botuliniques de type A.
- analyse : Glycoprotéines membranaires, Protéine SNAP-25, Protéines de tissu nerveux.
- effets indésirables : Inhibiteurs de la libération d'acétylcholine, Toxines botuliniques de type A.
- métabolisme : Vessie hyperactive.
- physiopathologie : Vessie hyperactive.
- traitement médicamenteux : Vessie hyperactive.
- Administration par voie vésicale, Adulte, Adulte d'âge moyen, Femelle, Humains, Liposomes, Miction, Mâle, Méthode en double aveugle, Projets pilotes, Sujet âgé, Sujet âgé de 80 ans ou plus, Urodynamique, Urothélium, Vessie urinaire.
English descriptors
- KwdEn :
- Acetylcholine Release Inhibitors (administration & dosage), Acetylcholine Release Inhibitors (adverse effects), Administration, Intravesical, Adult, Aged, Aged, 80 and over, Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (adverse effects), Double-Blind Method, Female, Humans, Liposomes, Male, Membrane Glycoproteins (analysis), Middle Aged, Nerve Tissue Proteins (analysis), Pilot Projects, Synaptosomal-Associated Protein 25 (analysis), Urinary Bladder (chemistry), Urinary Bladder, Overactive (drug therapy), Urinary Bladder, Overactive (metabolism), Urinary Bladder, Overactive (physiopathology), Urination (drug effects), Urodynamics (drug effects), Urothelium (chemistry).
- MESH :
- chemical , administration & dosage : Acetylcholine Release Inhibitors, Botulinum Toxins, Type A.
- chemical , adverse effects : Acetylcholine Release Inhibitors, Botulinum Toxins, Type A.
- chemical , analysis : Membrane Glycoproteins, Nerve Tissue Proteins, Synaptosomal-Associated Protein 25.
- chemistry : Urinary Bladder, Urothelium.
- drug effects : Urination, Urodynamics.
- drug therapy : Urinary Bladder, Overactive.
- metabolism : Urinary Bladder, Overactive.
- physiopathology : Urinary Bladder, Overactive.
- Administration, Intravesical, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Liposomes, Male, Middle Aged, Pilot Projects.
Abstract
Intradetrusor onabotulinumtoxinA (BoNT-A) injection benefits overactive bladder (OAB) patients, but increased postvoid residual (PVR) urine volume and urinary tract infection (UTI) remain risks. Intravesical instillation of liposomal BoNT-A instead of injection could prevent such adverse events.
DOI: 10.1016/j.eururo.2014.01.036
PubMed: 24555904
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002A25
- to stream PubMed, to step Curation: 002A12
- to stream PubMed, to step Checkpoint: 002A12
- to stream Ncbi, to step Merge: 001218
- to stream Ncbi, to step Curation: 001218
- to stream Ncbi, to step Checkpoint: 001218
Links to Exploration step
pubmed:24555904Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.</title><author><name sortKey="Kuo, Hann Chorng" sort="Kuo, Hann Chorng" uniqKey="Kuo H" first="Hann-Chorng" last="Kuo">Hann-Chorng Kuo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan. Electronic address: hck@tzuchi.com.tw.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien</wicri:regionArea><wicri:noRegion>Hualien</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Hsin Tzu" sort="Liu, Hsin Tzu" uniqKey="Liu H" first="Hsin-Tzu" last="Liu">Hsin-Tzu Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien</wicri:regionArea><wicri:noRegion>Hualien</wicri:noRegion></affiliation></author><author><name sortKey="Chuang, Yao Chi" sort="Chuang, Yao Chi" uniqKey="Chuang Y" first="Yao-Chi" last="Chuang">Yao-Chi Chuang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung</wicri:regionArea><wicri:noRegion>Kaohsiung</wicri:noRegion></affiliation></author><author><name sortKey="Birder, Lori A" sort="Birder, Lori A" uniqKey="Birder L" first="Lori A" last="Birder">Lori A. Birder</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Medicine and Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Medicine and Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Chancellor, Michael B" sort="Chancellor, Michael B" uniqKey="Chancellor M" first="Michael B" last="Chancellor">Michael B. Chancellor</name><affiliation wicri:level="2"><nlm:affiliation>Oakland University, William Beaumont School of Medicine, Royal Oak, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oakland University, William Beaumont School of Medicine, Royal Oak, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24555904</idno><idno type="pmid">24555904</idno><idno type="doi">10.1016/j.eururo.2014.01.036</idno><idno type="wicri:Area/PubMed/Corpus">002A25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002A25</idno><idno type="wicri:Area/PubMed/Curation">002A12</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A12</idno><idno type="wicri:Area/PubMed/Checkpoint">002A12</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A12</idno><idno type="wicri:Area/Ncbi/Merge">001218</idno><idno type="wicri:Area/Ncbi/Curation">001218</idno><idno type="wicri:Area/Ncbi/Checkpoint">001218</idno><idno type="wicri:Area/Main/Merge">001B84</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.</title><author><name sortKey="Kuo, Hann Chorng" sort="Kuo, Hann Chorng" uniqKey="Kuo H" first="Hann-Chorng" last="Kuo">Hann-Chorng Kuo</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan. Electronic address: hck@tzuchi.com.tw.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien</wicri:regionArea><wicri:noRegion>Hualien</wicri:noRegion></affiliation></author><author><name sortKey="Liu, Hsin Tzu" sort="Liu, Hsin Tzu" uniqKey="Liu H" first="Hsin-Tzu" last="Liu">Hsin-Tzu Liu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien</wicri:regionArea><wicri:noRegion>Hualien</wicri:noRegion></affiliation></author><author><name sortKey="Chuang, Yao Chi" sort="Chuang, Yao Chi" uniqKey="Chuang Y" first="Yao-Chi" last="Chuang">Yao-Chi Chuang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung</wicri:regionArea><wicri:noRegion>Kaohsiung</wicri:noRegion></affiliation></author><author><name sortKey="Birder, Lori A" sort="Birder, Lori A" uniqKey="Birder L" first="Lori A" last="Birder">Lori A. Birder</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Medicine and Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Medicine and Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Chancellor, Michael B" sort="Chancellor, Michael B" uniqKey="Chancellor M" first="Michael B" last="Chancellor">Michael B. Chancellor</name><affiliation wicri:level="2"><nlm:affiliation>Oakland University, William Beaumont School of Medicine, Royal Oak, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oakland University, William Beaumont School of Medicine, Royal Oak, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylcholine Release Inhibitors (administration & dosage)</term><term>Acetylcholine Release Inhibitors (adverse effects)</term><term>Administration, Intravesical</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum Toxins, Type A (adverse effects)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Liposomes</term><term>Male</term><term>Membrane Glycoproteins (analysis)</term><term>Middle Aged</term><term>Nerve Tissue Proteins (analysis)</term><term>Pilot Projects</term><term>Synaptosomal-Associated Protein 25 (analysis)</term><term>Urinary Bladder (chemistry)</term><term>Urinary Bladder, Overactive (drug therapy)</term><term>Urinary Bladder, Overactive (metabolism)</term><term>Urinary Bladder, Overactive (physiopathology)</term><term>Urination (drug effects)</term><term>Urodynamics (drug effects)</term><term>Urothelium (chemistry)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie vésicale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Glycoprotéines membranaires (analyse)</term><term>Humains</term><term>Inhibiteurs de la libération d'acétylcholine (administration et posologie)</term><term>Inhibiteurs de la libération d'acétylcholine (effets indésirables)</term><term>Liposomes</term><term>Miction ()</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Projets pilotes</term><term>Protéine SNAP-25 (analyse)</term><term>Protéines de tissu nerveux (analyse)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Toxines botuliniques de type A (administration et posologie)</term><term>Toxines botuliniques de type A (effets indésirables)</term><term>Urodynamique ()</term><term>Urothélium ()</term><term>Vessie hyperactive (métabolisme)</term><term>Vessie hyperactive (physiopathologie)</term><term>Vessie hyperactive (traitement médicamenteux)</term><term>Vessie urinaire ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetylcholine Release Inhibitors</term><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetylcholine Release Inhibitors</term><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Membrane Glycoproteins</term><term>Nerve Tissue Proteins</term><term>Synaptosomal-Associated Protein 25</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de la libération d'acétylcholine</term><term>Toxines botuliniques de type A</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéine SNAP-25</term><term>Protéines de tissu nerveux</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Urinary Bladder</term><term>Urothelium</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Urination</term><term>Urodynamics</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de la libération d'acétylcholine</term><term>Toxines botuliniques de type A</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Vessie hyperactive</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Vessie hyperactive</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Vessie hyperactive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intravesical</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Liposomes</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie vésicale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Liposomes</term><term>Miction</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Projets pilotes</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Urodynamique</term><term>Urothélium</term><term>Vessie urinaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Intradetrusor onabotulinumtoxinA (BoNT-A) injection benefits overactive bladder (OAB) patients, but increased postvoid residual (PVR) urine volume and urinary tract infection (UTI) remain risks. Intravesical instillation of liposomal BoNT-A instead of injection could prevent such adverse events.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B84 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001B84 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:24555904
|texte= Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:24555904" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |